TP方案联合华蟾素治疗晚期非小细胞肺癌的临床观察

Study of Huanchansu Injection Combined with TP Regimen in the Treatment of Patients with Advanced Non-small Cell Lung Cancer

目的探讨TP方案联合华蟾素注射液治疗晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的疗效及其对生存质量的影响。方法对64例晚期NSCLC患者采用完全随机分组法,分为TP方案联合华蟾素组32例,华蟾素20 mL,静脉滴入,1次/天,连用28天;多西他赛(Taxotere)75 mg/m2,静脉滴入,第1天;顺铂(DDP)25 mg/(m2.d),静脉滴入,第1～3天,21天为1个周期。TP方案组32例,多西他赛和DDP用法剂量同前。结果 TP方案联合华蟾素组近期有效率为53.1%(17/32),TP方案组为40.6%(13/32),差异无统计学意义,P>0.05;临床受益率TP方案联合华蟾素组(87.5%)高于TP方案组(68.8%),P<0.05。TP方案联合华蟾素组化疗时生存质量优于TP方案组,P<0.05。结论 TP方案联合华蟾素治疗晚期NCSLC能增加疗效,改善患者的生存质量,并具有保护骨髓的功能。

Objective To investigale the efficacy of TP regimen plus Huachansu injection in the treatment of patients with advanced non-small cell lung cancer.Methods 64 patients with advanced non-small cell lung cancer were divided into TP regimen plus Huachansu injection group and TP alone group.TP regimen was the same in both groups,which included taxotere 75 mg/m2,d1,and DDP 25 mg/（m2·d）,d1～d3.Patients in the combined treatment group also received Huachansu 20 mL,d1～d28.Results The response rate was 53.1%（17/32） and 40.6%（13/32）,which was not significantly different.The clinical benefit rate（CR＋PR＋SD） of two groups was 87.5% and 68.8%,which was significantly different in favor of the combined treatment（P0.05）.Pain relief,improvement of KPS,and weight gain were significantly better in the combined group.Conclusion TP combined with Huachansu injection is better than TP alone in the treatment of patients with advanced non small cell lung cancer.